1,824 Shares in Agilent Technologies, Inc. (NYSE:A) Bought by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI bought a new stake in shares of Agilent Technologies, Inc. (NYSE:A) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,824 shares of the medical research company’s stock, valued at approximately $271,000.

Other large investors also recently modified their holdings of the company. Livelsberger Financial Advisory acquired a new stake in Agilent Technologies in the third quarter valued at $28,000. Crewe Advisors LLC raised its stake in shares of Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Ridgewood Investments LLC bought a new position in shares of Agilent Technologies during the second quarter worth about $29,000. Larson Financial Group LLC grew its stake in Agilent Technologies by 29,300.0% in the first quarter. Larson Financial Group LLC now owns 294 shares of the medical research company’s stock worth $43,000 after purchasing an additional 293 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new stake in Agilent Technologies in the second quarter valued at about $39,000. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Agilent Technologies Trading Down 1.7 %

Shares of A stock opened at $130.72 on Friday. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35. The firm has a market capitalization of $38.14 billion, a PE ratio of 30.90, a price-to-earnings-growth ratio of 6.96 and a beta of 1.05. The stock has a fifty day moving average of $140.91 and a two-hundred day moving average of $138.59. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the prior year, the company posted $1.43 earnings per share. The company’s quarterly revenue was down 5.6% compared to the same quarter last year. As a group, research analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were paid a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a yield of 0.72%. The ex-dividend date was Tuesday, October 1st. Agilent Technologies’s payout ratio is currently 22.22%.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,995 shares of company stock worth $1,739,510. 0.33% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently commented on A shares. Citigroup lifted their target price on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. TD Cowen boosted their target price on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Evercore ISI raised their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Wells Fargo & Company began coverage on shares of Agilent Technologies in a research report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price objective for the company. Finally, Barclays raised their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $144.36.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.